Injectable PrEP shot for HIV prevention in higher-risk adults
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be assigned male at birth (cisgender men, non-binary people assigned male, or transgender women and men) and be 18–30 years old
- Have had anal sex with a partner assigned male at birth within the last 6 months
- Be looking for PrEP (HIV prevention) and have not used cabotegravir LA or TDF/FTC PrEP before
- Have negative HIV testing at enrollment (both rapid test and, if using injectable cabotegravir, an undetectable HIV RNA test)
- Do not have significant liver problems and avoid certain medicines that can lower cabotegravir levels
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a long-acting HIV prevention shot (Cabotegravir) or a vaginal ring (DapiRing) along with sexual health services for young people. It aims to find the best way to prevent HIV and support overall health.
This research studies how two types of long-acting birth control (a shot called cabotegravir and an implant) work in your body after pregnancy, and how they interact with HIV prevention or treatment. The study helps doctors understand the best doses and timing for women like you.
This study helps healthcare providers and clinics deliver long-acting injectable PrEP (a preventive HIV medication given as an injection) more effectively. Researchers will study how clinics can better implement and offer this option to patients who need it.
This trial tests a nurse-run program that makes it easier to get long-acting injectable PrEP (cabotegravir) for HIV prevention. It aims to see if nurses can start and provide this shot quickly at your regular clinic visits.
This study follows people taking a new long-acting HIV prevention injection called LA CAB (cabotegravir). Researchers want to understand how well it works, how people use it, and what side effects occur in real-world NHS clinics.
This study offers three ways to prevent HIV: a shot every two months (injectable PrEP), daily pills, or a vaginal ring. Researchers in Cape Town will help you choose the option that fits your life best.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.